Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies.

Passweg JR, Zhang MJ, Rocha V, Kan F, Champlin RE, Isola LM, Gee AP, Gibson J, Laughlin MJ, Lazarus HM, Loren A, Marks DI, Gratwohl A, Eapen M.

Biol Blood Marrow Transplant. 2011 Dec;17(12):1869-73. doi: 10.1016/j.bbmt.2011.07.008.

3.

Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.

Pérez-Simón JA, Caballero D, Diez-Campelo M, Lopez-Pérez R, Mateos G, Cañizo C, Vazquez L, Vidriales B, Mateos MV, Gonzalez M, San Miguel JF.

Leukemia. 2002 Aug;16(8):1423-31. Review.

4.

HLA-haploidentical stem cell transplantation for hematologic malignancies.

Fuchs EJ, Huang XJ, Miller JS.

Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S57-63. doi: 10.1016/j.bbmt.2009.10.032. Review.

5.

Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction.

Strober S, Spitzer TR, Lowsky R, Sykes M.

Semin Immunol. 2011 Aug;23(4):273-81. doi: 10.1016/j.smim.2011.05.001. Review.

6.

Graft failure after allogeneic hematopoietic cell transplantation.

Mattsson J, Ringdén O, Storb R.

Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):165-70. doi: 10.1016/j.bbmt.2007.10.025. Review. Erratum in: Biol Blood Marrow Transplant. 2008 Nov;14(11):1317-8.

7.

Allogeneic hematopoietic cell transplantation: the state of the art.

Gyurkocza B, Rezvani A, Storb RF.

Expert Rev Hematol. 2010 Jun;3(3):285-99. doi: 10.1586/ehm.10.21. Review.

8.

Evolving approaches of hematopoietic stem cell-based therapies to induce tolerance to organ transplants: the long road to tolerance.

Leventhal J, Miller J, Abecassis M, Tollerud DJ, Ildstad ST.

Clin Pharmacol Ther. 2013 Jan;93(1):36-45. doi: 10.1038/clpt.2012.201. Review.

9.

The major histocompatibility complex: a model for understanding graft-versus-host disease.

Petersdorf EW.

Blood. 2013 Sep 12;122(11):1863-72. doi: 10.1182/blood-2013-05-355982. Review.

10.

Who is fit for allogeneic transplantation?

Deeg HJ, Sandmaier BM.

Blood. 2010 Dec 2;116(23):4762-70. doi: 10.1182/blood-2010-07-259358. Review.

11.

New approaches in alternative donor transplantation.

Fernandez Vina M, Heslop HE, Barker JN.

Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S91-6. doi: 10.1016/j.bbmt.2012.10.027. Review. No abstract available.

12.

Therapy-related noninfectious complications in patients with hematologic malignancies: high-resolution computed tomography findings.

Brodoefel H, Faul C, Salih H, Vogel W, Fenchel M, Horger M.

J Thorac Imaging. 2013 Jan;28(1):W5-11. doi: 10.1097/RTI.0b013e31822031f0. Review.

PMID:
21795994

Supplemental Content

Support Center